I agree wholeheartedly that $1.5 billion would be too cheap.
I also agree that we've got a great chance to get a Breakthrough Device Designation but we won't get marketing authorization without a much larger trial proving safety and efficacy. Is there a path to a Humanitarian Device Exemption (and sales of up to 8k per year) for ViV? Potentially. I'm still kind of skeptical and am sure it won't be granted based on Canadian procedures but the company did say in the financing press release that money could be used for ViV trials. Also, in the most recent Proactive interview Wayne called ViV one to watch.
AVR Price at posting:
$19.10 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)